Get the Stockscreener App
3.38
7.30%
0.23
Eledon Pharmaceuticals Inc stock is traded at $3.38, with a volume of 634.88K.
It is up +7.30% in the last 24 hours and up +21.15% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$3.15
Open:
$3.11
24h Volume:
634.88K
Relative Volume:
1.32
Market Cap:
$202.40M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-1.8883
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
-6.63%
1M Performance:
+21.15%
6M Performance:
-25.22%
1Y Performance:
+16.96%
1-Day Range:
$3.07
$3.43
1-Week Range:
$2.90
$3.8195
52-Week Range:
$2.375
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.38 | 188.63M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Eledon Pharmaceuticals Inc. stock outlook for YEARFree Entry Zone Strategy for Consistent Profit - Newser
Combining price and volume data for Eledon Pharmaceuticals Inc.ROI Focused Setup With Drawdown Analysis - Newser
What are analysts’ price targets for Eledon Pharmaceuticals Inc. in the next 12 monthsStock Strategy Data Feed With High Returns - jammulinksnews.com
What are the latest earnings results for Eledon Pharmaceuticals Inc.Wealth Building Trend Scanner For Smart Trading - jammulinksnews.com
What institutional investors are buying Eledon Pharmaceuticals Inc. stockMarket Forecast Alerts To Watch Now - jammulinksnews.com
What are Eledon Pharmaceuticals Inc. company’s key revenue driversTop Growth Watchlist For 2025 - jammulinksnews.com
How Eledon Pharmaceuticals Inc. stock performs during market volatilityDividend Strategy Summary With 10-Year Outlook - Newser
What is Eledon Pharmaceuticals Inc. company’s growth strategyRetirement Planning Entry Points For Consistent Profits - jammulinksnews.com
Real time alert setup for Eledon Pharmaceuticals Inc. performanceSmart Risk Entry Zone Technical Analysis - Newser
Visual analytics tools that track Eledon Pharmaceuticals Inc. performanceAI Screener for Daily Stock Forecast - Newser
Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress - Insider Monkey
How strong is Eledon Pharmaceuticals Inc. company’s balance sheetLow Risk Recommendation With High Returns - jammulinksnews.com
Can Eledon Pharma's Tegoprubart Transform The Future Of Kidney Transplants? - RTTNews
Detecting price anomalies in Eledon Pharmaceuticals Inc. with AIFree Stock Selection With High Accuracy - Newser
Can trapped investors hope for a rebound in Eledon Pharmaceuticals Inc.Volume Based Swing Signal Prediction Map - Newser
Eledon Pharmaceutical To Host A Conference Call And Webcast On Wednesday, August 6, 2025 To Discuss Updated Clinical Data From Its Ongoing Open-label Phase 1b Study Evaluating Tegoprubart For The Prevention Of Rejection In Subjects Undergoing - 富途牛牛
Eledon to host conference call on kidney transplant study results By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals to Host a Conference Call to Discuss - GlobeNewswire
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 - Yahoo Finance
Is Eledon Pharmaceuticals Inc. stock a good hedge against inflationFree Low Risk Buy Zone Opportunity Watch - Newser
Eledon Pharmaceuticals Inc. Shows Early Signs of Technical StrengthInvestment Playbook for Growing Markets Shared - metal.it
Does Eledon Pharmaceuticals Inc. qualify in momentum factor screeningWeekly Trend Screener with Momentum Picks - Newser
Volatility clustering patterns for Eledon Pharmaceuticals Inc.Free Consistent Gain Investment Strategies - Newser
What is the risk reward ratio of investing in Eledon Pharmaceuticals Inc. stockRetirement Planning Target Finder Backed By Experts - jammulinksnews.com
Has Eledon Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewFree Investment Playbook for Growing Markets - Newser
What catalysts could drive Eledon Pharmaceuticals Inc. stock higher in 2025Expert Picks Tracker For Beginners - jammulinksnews.com
What makes Eledon Pharmaceuticals Inc. stock price move sharplyAchieve consistent profits with proven methods - jammulinksnews.com
Does Eledon Pharmaceuticals Inc. stock perform well during market downturnsAchieve breakthrough financial growth - jammulinksnews.com
Reviewing Sagimet Biosciences (NASDAQ:SGMT) & Eledon Pharmaceuticals (NASDAQ:ELDN) - Defense World
Why is Eledon Pharmaceuticals Inc. stock attracting strong analyst attentionRapid portfolio appreciation - jammulinksnews.com
How many analysts rate Eledon Pharmaceuticals Inc. as a “Buy”Invest confidently with proven investment plans - jammulinksnews.com
Published on: 2025-07-28 01:06:10 - jammulinksnews.com
Eledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated by Analysts at Craig Hallum - Defense World
Published on: 2025-07-27 20:41:15 - jammulinksnews.com
Eledon Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveProfit Focused Trade Alerts - Newser
Eledon Pharmaceuticals (NASDAQ:ELDN) Now Covered by Analysts at Craig Hallum - Defense World
Craig Hallum Upgrades Eledon Pharmaceuticals (NASDAQ:ELDN) to “Strong-Buy” - Defense World
What drives Eledon Pharmaceuticals Inc. stock priceHigh-yield investments - PrintWeekIndia
Is Eledon Pharmaceuticals Inc. a good long term investmentConsistently high returns - PrintWeekIndia
Should I buy Eledon Pharmaceuticals Inc. stock before earningsFree Market Volatility Navigation Tips - jammulinksnews.com
Eledon Pharmaceuticals (ELDN) Receives Buy Rating from Craig-Hallum | ELDN Stock News - GuruFocus
What analysts say about Eledon Pharmaceuticals Inc. stockSkyrocketing returns - PrintWeekIndia
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):